Good News for Jazz, Celldex, Inventiva & Illumina
Jazz Pharmaceuticals Good News

Jazz Pharmaceuticals (JAZZ) announced along with its partner PharmaMar (MSE: PHM) that the U.S. FDA has approved Zepzelca™ (lurbinectedin) for adults with metastatic small cell lung cancer (SCLC) and disease progression on or after platinum-based chemotherapy. 

Zepzelca was granted accelerated approval based on the overall response rate (ORR) and duration of response . . .